Home › Alzheimer's Disease › NCT07787182

A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

Who can join

Ages 18 to 85 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Participants must meet eligibility criteria in the ATMP screening protocol before entry into the treatment study.

Exclusion Criteria:

* Have known allergies to LY4405094, related compounds (including remternetug), or any components of the formulation, including LY4405094.
* Have known allergic reactions to adhesive or hydrogels or a family history of adhesive skin allergies.

About the study

The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the Clinical Research Unit (CRU). For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 25 weeks and will include a 3-day stay in the CRU.

What is being tested

• LY4405094 (drug)
• LY4405094 (drug)
• Placebo (drug)
• Placebo (drug)
• Florbetapir F18 (other)
• Florbetaben F 18 (other)

Sponsor: Eli Lilly and Company · Participants: 68 · Started: Oct 14, 2025

Contact the study team

• Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · Phone: 1-317-615-4559

Official record on ClinicalTrials.gov — NCT07787182

Locations in the U.S.

Conditions

• Alzheimer's Disease
• Amyloid Plaque

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.